Emerging Vector-Borne Diseases in Central Africa: A Threat to Animal Production and Human Health

Although the potential for livestock production is high in Central Africa, it is not an important economic activity because of disease constraints, primarily trypanosomiasis transmitted by tsetse flies. Recently, a growing number of vector-borne diseases have also emerged in that region. Indeed, there is a progressive expansion of trypanosomiasis in known tsetse-free areas in the Far North of Cameroon, mechanically transmitted by Tabanidae. In the beginning of year 2019, there was an epidemic of African horse sickness (AHS) in Cameroon for the first time. In the meantime, AHS was also declared in Chad and reported in Nigeria. Besides, new cases of Rift Valley fever (RVF) are regularly detected in both Cameroon and Chad. The relative significance of most vector-borne diseases (VBDs) in livestock is difficult to quantify, because there is no study on their socioeconomic impact. But, certain VBDs have significant impact on food production, and others such as RVF can be transmitted to humans. Impact of VBDs on human health, animal health and trade, as well as the transboundary nature of these diseases means there is a need for regional coordination and cooperation to address challenges. This can be successfully achieved with One Health approach

In vitro activity of commercial formulation and active principle of trypanocidal drugs against blooststreams forms of Trypanosoma brucei gambiense

The in vitro trypanocidal activities of 4 commercial formulations Ornidyl®, Pentamidine isethionate®, Germanin® and Lampit® and their corresponding active principles (Dl-difluoromethylornithine, pentamidine isethionate, suramine and 5-nitrofuran) were compared against Trypanosoma brucei gambiense. Differences of minimum inhibitory concentration (MIC) were observed between Ornidyl® and Dl-difluoromethylornithine and between Lampit® and 5-nitrofuran. For RO 15 strain and the comparison of Ornidyl®/ DFMO, the MIC when using the commercial drug was more than twice the MIC value obtained with the active principle. For all 3 trypanosome strains, MICs were identical for Lampit® and 5-nitrofuran but the MIC with the commercial formulation was twice the MIC obtained with the active principle. The active principles, rather than commercial formulations, should be used for standardization of in vitro assay protocols. Key words: In vitro activity, trypanocidal drugs, commercial formulations, Trypanosoma brucei gambiense. African Journal of Biotechnology Vol.2(11) 2003: 474-47